J&J Secures $750 Million in Blackstone R&D Funding, Pending Ollin Closing
Article excerpt
Highlighted: the sentence this signal was extracted from
Blackstone announced on November 16, 2026 that funds managed by Blackstone Life Sciences will provide $750 million to Johnson & Johnson ( JNJ ) for Phase 3 development of OLN324, an investigational therapy for serious retinal vascular diseases. The agreement is contingent on Johnson & Johnson completing its proposed acquisition of Ollin Biosciences. The money will be paid over multiple years and fully fund that development, according to Johnson & Johnson's companion announcement. The clinical program covers wet age-related macular degeneration and diabetic macular edema. In return, Blackstone will be eligible for certain regulatory and sales milestone payments and single-digit royalties. The arrangement separates the company acquisition from late-stage research financing. Johnson & Johnson would add OLN324 to its pipeline through the Ollin purchase, while Blackstone would finance the trials in exchange for milestone payments and royalties. Blackstone would therefore be a funding partner in the acquired drug's development rather than a buyer of Ollin. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the agreement expands Blackstone's relationship with Johnson & Johnson and demonstrates its ability to provide capital at scale for pharmaceutical development. Johnson & Johnson has entered into a definitive agreement to acquire Ollin, a clinical-stage...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
